Mirikizumab for older adults with Crohn's or ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests a medication called mirikizumab (an injection) in people over 60 with moderate to severe Crohn's disease or ulcerative colitis. The goal is to see if it effectively reduces inflammation and helps symptoms, while also checking how safe it is for older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years of age or older.
- You have a confirmed diagnosis of moderate to severe Crohn's disease or ulcerative colitis.
- You have not had major bowel surgery in the last 3 months.
- You do not have an active infection requiring antibiotics or antiviral treatment.
- You have no history of cancer in the past 5 years, except for fully removed skin cancers that have not spread.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This trial tests if mirikizumab can reduce deep inflammation in the intestine walls in people with active Crohn's disease. It may help heal damage that shows up on an MRI scan.
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
This study looks at whether a special ultrasound test can better track how well a treatment called mirikizumab is working for people with moderate-to-severe ulcerative colitis. It may help doctors see if the treatment is reducing inflammation in the bowel more accurately than current methods.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.